Brevi-T Bio announced its pioneering drug abuse monitoring, assessment, and evaluation system. The first-of-its-kind ecosystem and action plan for public health management solves the major problems associated with accurately identifying the presence, type, and scale of drug use.
SAN DIEGO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- Brevi-T Bio today announced its pioneering drug abuse monitoring, assessment, and evaluation system. The first-of-its-kind ecosystem and action plan for public health management solves the major problems associated with accurately identifying the presence, type, and scale of drug use.
There is growing concern over the introduction and proliferation of new and even more deadly Drugs of Abuse. To respond rapidly to a crisis in its early stages, it's essential to have real-time warnings when drug use patterns are shifting.
Unfortunately, significant challenges exist with the tracking of drugs, largely because of the limitations of flawed drug use reporting. Drug use is generally conducted privately and unofficially, and is largely confidential and undisclosed, but the data on which drug consumption trends are based typically rely on self-reporting by the drug users themselves. Consequently, methods used to identify the prevalence of drug abuse, such as population surveys, crime statistics, and medical records, depend on the honesty of the respondent and may not reveal the true picture and problem.
Further, there is usually a long lag before results from surveys are available to view, sometimes years later. Imprecise and slow data mean that the police, public health officials, researchers, educators, parents, and even drug users don't know what risks are lurking until it's too late.
Wastewater analysis is a proven, non-intrusive, anonymous, and cost-efficient method of gathering objective and reliable data on drug use in a community, district, school, or workplace. The results are not subject to respondent bias and reveal a more accurate and truthful picture of the drugs being consumed.
Timely and reliable data on the scale, type, and demographics of illegal drug use is essential to understand drug consumption patterns, identify or improve action plans and procedures, and to ensure the maximum reduction of adverse – and often lethal – effects of drug abuse.
For the first time ever, Brevi-T introduces PULSE, a centralized database with standardized collection and testing methods, environmental demographics, packaged in a user-friendly interface. The breakthrough single source solution precisely aggregates, interprets, and compares real-time data for a wide range of substances in a single panel.
In addition to identifying a broad range of amphetamines, barbiturates, opioids, and stimulants, PULSE analyzes patterns, predicts trends, and provides vital context for decision-makers, arming them with accurate information to assist with the implementation of strategies aimed at addiction intervention, prevention, treatment, and recovery.
The ability to spot trends is crucial for decision makers to evaluate the efficacy of their drug prevention programs and make changes if they aren't delivering expected results. Brevi-T's single source approach will help implementers identify specific drugs that may be causing a pandemic amongst their populations, and zero in on the specific drug so they can execute an action plan to help save lives.
State-of-the-art cloud-based software integrates automated wastewater testing, individual swab testing (if required), data enrichment, advanced analytics, rapid reporting, and a real-time alert system to deliver accurate drug prevalence results. Additionally, PULSE provides consistent and automated sample process management and logistics through its mobile apps, which is critically important for identifying factors that may result in false positives or false negatives.
The PULSE dashboard interface presents vital information clearly and easily accessible, allowing users with no technical experience to quickly understand results, and accelerate their life-saving work in preventing and eradicating one of today's most devastating health crises.
"The opioid epidemic has been a problem in this country for decades and the medical system, based on one-at-a-time testing, has not provided a solution," said Paul Scott, CEO of Avrok Biosciences, and CTO of Brevi-T Bio. "Brevi-T's PULSE system is an epidemiological approach, testing at the large groups level and tracking that use over time. This allows entities, both private and public, to identify whether their solutions are working in real time and allows for more intelligent targeted testing where merited."
About Brevi-T Bio
Brevi-T, a joint venture between InterOme, a digital health enterprise, and Avrok Biosciences is tackling some of the world's biggest public health challenges, including infectious diseases, substance abuse, and environmental contaminants through improved practices, plans and policies. Brevi-T's mission is to make the world a healthier place, by creating the means to detect, assess, and manage public health risk factors to prevent the spread of epidemics. Brevi-T's goal is to use actionable data for the best possible individual and public health outcomes.
For additional information, please visit https://www.brevitbio.com
Media Contact
Corina Shtir, PhD, CEO, Brevi-T Bio, 1 858-294-0204, [email protected]
SOURCE Brevi-T Bio
Share this article